Roscovitine Inhibits CaV3.1 (T-Type) Channels by Preferentially Affecting Closed-State Inactivation
- 1 February 2012
- journal article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 340 (2) , 463-472
Abstract
T-type calcium channels (CaV3) play an important role in many physiological and pathological processes, including cancerogenesis. CaV3 channel blockers have been proposed as potential cancer treatments. Roscovitine, a trisubstituted purine, is a cyclin-dependent kinase (CDK) inhibitor that is currently undergoing phase II clinical trials as an anticancer drug and has been shown to affect calcium and potassium channel activity. Here, we investigate the effect of roscovitine on CaV3.1 channels. CaV3.1 channels were transiently expressed in human embryonic kidney 293 cells, and currents were recorded by using the whole-cell patch-clamp technique. Roscovitine blocks CaV3.1 channels with higher affinity for depolarized cells (EC50 of 10 μM), which is associated with a negative shift in the voltage dependence of closed-state inactivation. Enhanced inactivation is mediated by roscovitine-induced acceleration of closed-state inactivation and slowed recovery from inactivation. Small effects of roscovitine were also observed on T-channel deactivation and open-state inactivation, but neither could explain the inhibitory effect. Roscovitine inhibits CaV3.1 channels within the therapeutic range (10–50 μM) in part by stabilizing the closed-inactivated state. The ability of roscovitine to block multiple mediators of proliferation, including CDKs and CaV3.1 channels, may facilitate its anticancer properties.Keywords
This publication has 47 references indexed in Scilit:
- Using induced pluripotent stem cells to investigate cardiac phenotypes in Timothy syndromeNature, 2011
- Mechanisms of inhibition of CaV3.1 T-type calcium current by aliphatic alcoholsNeuropharmacology, 2010
- Roscovitine Binds to Novel L-channel (CaV1.2) Sites That Separately Affect Activation and InactivationJournal of Biological Chemistry, 2010
- State-dependent block of HERG potassium channels byR-roscovitine: implications for cancer therapyAmerican Journal of Physiology-Cell Physiology, 2009
- The Timothy syndrome mutation of cardiac CaV1.2 (L‐type) channels: multiple altered gating mechanisms and pharmacological restoration of inactivationThe Journal of Physiology, 2009
- Finding multiple target optimal intervention in disease‐related molecular networkMolecular Systems Biology, 2008
- Xenohormesis: Sensing the Chemical Cues of Other SpeciesCell, 2008
- T-type Ca2+ channel expression in human esophageal carcinomas: A functional role in proliferationCell Calcium, 2008
- Roscovitine, a cyclin‐dependent kinase inhibitor, affects several gating mechanisms to inhibit cardiac L‐type (Ca(V)1.2) calcium channelsBritish Journal of Pharmacology, 2007
- A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 daysBritish Journal of Cancer, 2006